DCPH Key Statistics, Chart & Performance
The current stock price of DCPH is 25.59 USD. In the past month the price increased by 0.91%. In the past year, price increased by 77.34%.
DCPH Latest News, Press Relases and Analysis
DCPH Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.09 | 402.18B | ||
| AMGN | AMGEN INC | 15.76 | 185.50B | ||
| GILD | GILEAD SCIENCES INC | 15.57 | 158.22B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.89 | 110.80B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.43 | 83.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 872.78 | 58.35B | ||
| INSM | INSMED INC | N/A | 43.23B | ||
| NTRA | NATERA INC | N/A | 32.54B | ||
| BIIB | BIOGEN INC | 10.87 | 26.67B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.51 | 22.09B | ||
| INCY | INCYTE CORP | 16.46 | 20.63B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.21B |
Related stock screener links
About DCPH
Company Profile
Deciphera Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering important new medicines to patients for the treatment of cancer. The company is headquartered in Waltham, Massachusetts and currently employs 300 full-time employees. The company went IPO on 2017-09-28. The firm has developed a switch-control kinase inhibitor platform in kinase biology to execute its strategy to develop a portfolio of medicines. The firm's QINLOCK, is a switch-control kinase inhibitor, engineered using its drug discovery platform and developed for the treatment of fourth-line gastrointestinal stromal tumor (GIST). The firm has two additional clinical-stage assets, vimseltinib and DCC-3116. Vimseltinib is an investigational, orally administered, potent, and highly selective switch-control kinase inhibitor of the colony stimulating factor 1 receptor (CSF1R). Vimseltinib is in a pivotal phase III study in patients with tenosynovial giant cell tumor (TGCT). DCC-3116 is an investigational, orally administered, potent, and highly selective switch-control inhibitor of the ULK kinase.
Company Info
DECIPHERA PHARMACEUTICALS IN
200 Smith St
Waltham MASSACHUSETTS 02451 US
CEO: Steven L. Hoerter
Employees: 300
Phone: 17812096400
DECIPHERA PHARMACEUTICALS IN / DCPH FAQ
What does DCPH do?
Deciphera Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering important new medicines to patients for the treatment of cancer. The company is headquartered in Waltham, Massachusetts and currently employs 300 full-time employees. The company went IPO on 2017-09-28. The firm has developed a switch-control kinase inhibitor platform in kinase biology to execute its strategy to develop a portfolio of medicines. The firm's QINLOCK, is a switch-control kinase inhibitor, engineered using its drug discovery platform and developed for the treatment of fourth-line gastrointestinal stromal tumor (GIST). The firm has two additional clinical-stage assets, vimseltinib and DCC-3116. Vimseltinib is an investigational, orally administered, potent, and highly selective switch-control kinase inhibitor of the colony stimulating factor 1 receptor (CSF1R). Vimseltinib is in a pivotal phase III study in patients with tenosynovial giant cell tumor (TGCT). DCC-3116 is an investigational, orally administered, potent, and highly selective switch-control inhibitor of the ULK kinase.
What is the current price of DCPH stock?
The current stock price of DCPH is 25.59 USD. The price increased by 0.08% in the last trading session.
Does DCPH stock pay dividends?
DCPH does not pay a dividend.
What is the ChartMill rating of DECIPHERA PHARMACEUTICALS IN stock?
DCPH has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
Which stock exchange lists DCPH stock?
DCPH stock is listed on the Nasdaq exchange.
What is the market capitalization of DCPH stock?
DECIPHERA PHARMACEUTICALS IN (DCPH) has a market capitalization of 2.21B USD. This makes DCPH a Mid Cap stock.
What is the next earnings date for DCPH stock?
DECIPHERA PHARMACEUTICALS IN (DCPH) will report earnings on 2024-08-07, before the market open.
DCPH Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to DCPH. When comparing the yearly performance of all stocks, DCPH is one of the better performing stocks in the market, outperforming 97.48% of all stocks.
DCPH Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to DCPH. No worries on liquidiy or solvency for DCPH as it has an excellent financial health rating, but there are worries on the profitability.
DCPH Financial Highlights
Over the last trailing twelve months DCPH reported a non-GAAP Earnings per Share(EPS) of -2.21. The EPS increased by 5.96% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -45.24% | ||
| ROE | -60.25% | ||
| Debt/Equity | 0 |
DCPH Forecast & Estimates
16 analysts have analysed DCPH and the average price target is 27.25 USD. This implies a price increase of 6.47% is expected in the next year compared to the current price of 25.59.
For the next year, analysts expect an EPS growth of 5.08% and a revenue growth 25.31% for DCPH